Simvastatin Improves Neutrophil Function and Clinical Outcomes in Pneumonia. A Pilot Randomized Controlled Clinical Trial

• Published in: American journal of respiratory and critical care medicine Vol. 200; no. 10; pp. 1282 - 1293
• Main Authors: Sapey, Elizabeth, Patel, Jaimin M, Greenwood, Hannah, Walton, Georgia M, Grudzinska, Frances, Parekh, Dhruv, Mahida, Rahul Y, Dancer, Rachel C A, Lugg, Sebastian T, Howells, Philip A, Hazeldine, Jon, Newby, Paul, Scott, Aaron, Nightingale, Peter, Hill, Adam T, Thickett, David R
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 15.11.2019
• Subjects: Aged; Antibiotics; Clinical outcomes; Clinical trials; Community-Acquired Infections - drug therapy; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Male; Middle Aged; Neutrophils; Neutrophils - drug effects; Original; Pilot Projects; Pneumonia; Pneumonia - drug therapy; Sepsis; Sepsis - drug therapy; Simvastatin - therapeutic use; Treatment Outcome; innate immunity; pneumonia; statin; elderly care; sepsis
• ISSN: 1073-449X; 1535-4970; 1535-4970
• DOI: 10.1164/rccm.201812-2328OC

Population studies suggest improved sepsis outcomes with statins, but the results of randomized controlled trials in patients with sepsis and organ dysfunction in critical care settings have broadly been negative. data suggest that statins modulate age-related neutrophil functions, improving neutrophil responses to infection, but only in older patients and at high doses. To determine if high-dose simvastatin improves neutrophil functions and is safe and tolerated in hospitalized older adults with community-acquired pneumonia with sepsis (CAP + S) not admitted to critical care. We conducted a randomized, double-blind, placebo-controlled pilot study of simvastatin 80 mg or placebo for 7 days for patients with CAP + S aged 55 years or older admitted to a secondary care hospital. The Day 4 primary endpoint was change in neutrophil extracellular trap formation (NETosis). Day 4 secondary endpoints included neutrophil chemotaxis, safety and tolerability, Sequential Organ Failure Assessment score, mortality, readmission, and markers of tissue degradation/inflammation. Four days of simvastatin adjuvant therapy in patients with CAP + S was associated with improvements in systemic neutrophil function (NETosis and chemotaxis), a reduction in systemic neutrophil elastase burden, and improved Sequential Organ Failure Assessment scores compared with placebo. A analysis demonstrated that simvastatin therapy was associated with improved hospitalization-free survival compared with placebo. Simvastatin was well tolerated in this elderly and multimorbid patient group with common coprescription of macrolide antibiotics. This pilot study supports high-dose simvastatin as an adjuvant therapy for CAP + S in an older and milder disease cohort than assessed previously. A definitive multicenter study is now warranted in this population to assess the likelihood of benefit and harm.Clinical trial registered with EudraCT (2012-00343-29).